Phosphodiesterase 4 inhibitors reduce the proinflammatory mediators and cytokines in atopic dermatitis patients. Difamilast is the new selective phosphodiesterase 4 inhibitor that has proven its safety and efficacy for mild-to-moderate atopic dermatitis in their Phase II trial. This is a Phase III, superiority, double-blind, vehicle-controlled, par
535 Reached
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Rubella Syndrome in Neonate
1394 Reached12 Comments9 Likes
Black Lesion in Old Female
1966 Reached5 Comments11 Likes
Chronic Hyperplastic Candidiasis Of The Oral Mucosa
856 Reached9 Comments11 Likes